Effect of an Intensive Food-as-Medicine Program on Health and Health Care Use: A Randomized Clinical Trial

Joseph Doyle, MIT Sloan School of Management Marcella Alsan, Harvard Kennedy School Nicholas Skelley, MIT Sloan Health Systems Initiative Yutong Lu, MIT Sloan Health Systems Initiative John Cawley, Cornell University

NIH Pragmatic Trials Collaboratory: Grand Rounds March 1, 2024



## Introduction

## Background Intervention

## Data

# Randomized design

## Results




Diabetes is common and costly (ADA, 2018; CDC 2018) 9% of the US (and expected to increase) 300,000 premature deaths / year \$330bn in annual healthcare spending

Sustained reduction in HbA1c from poor to fair→\$3-5K/year in cost savings (Juarez et al., 2013; Wagner et al., 2001)

Food insecurity is associated with Diabetes (Seligman et al., 2014; Berkowitz et al., 2014)





## Social risk factors

https://hitconsultant.net/

White House Conference; Congressional Hearings; Rockefeller Foundation

Medicare Advantage

Medicaid demonstrations



Large literature on diets and health outcomes (Sacks et al., 2001; Sargrad et al., 2005; review by Micha et al., 2017; Estruch et al., *NEJM* 2013 PREDIMED Trial & "Mediterranean Diet")

Food Insecurity & Poor Health

Food-as-Medicine Observational Studies

Berkowitz et al. (2018, 2019a)

Gurvey et al. 2013; Palar et al., 2017; Feinberg et al. 2018

Large correlation w/ improved health (~30% reduction in hospitalization)

JOSEPH DOYLE, MIT SLOAN

Seligman et al., 2018: RCT of food-bank intervention (N=409) Improvement in food insecurity but no effect on HbA1c

Medically-tailored meals:

Go et al. 2022: null effect on re-hospitalization Rock et al., 2016: short-run reduction in weight

Ferrer et al. 2019 pilot RCT of produce delivery: improvement in HbA1c



## Brick-and-Mortar Clinics



Prescribe healthy meals to food-insecure patients w/ diabetes "Fill" the prescription each week at the program's clinic

10+ meals/week for participants and their families

Staffing: dietitian, nurse, community health worker

Education

About nutrition: dietitian and nurses; recipes

About diabetes: Diabetes Self Management Program (optional)

Screen for complications and close care gaps

Intensive

Average duration: 1 year Average cost: \$2000 per participant

Diet based on American Diabetes Association plate method



Fruits & Vegetables Beans -resh: Mushrooms Bag & Small Red beans Bag of Pinto beans Brussel Sproul 3 White Botatoes Blackeyed Peas Sweet Potatoes Cycumber Northern Beans leas Apple Silces Romaine hearts Lefture CORN Jalad Uressing Bananas Eggplant Pollock Tunalcanned Durprise Me Cannec Applesauce Green Beans Entrée Options Reaches mandarin Garges diced Tomatoes Recipe Kit !! The Bean Saladi Turkey ground Joseph Dove Billie Dernes Frozen

Diet based on American Diabetes Association plate method

- Recent menu included:
- Recipe kit for 3 bean salad
- Fish: pollock and tuna (canned)
- Poultry: chicken breasts and ground turkey
- Fresh Fruits & Vegetables: mushrooms, Brussels sprouts, carrots, broccoli, romaine hearts, cucumber, eggplant, beans, peas, bananas, kiwi
- Canned / bottled: applesauce, peaches, mandarin oranges, green beans, diced tomatoes, various beans, salad dressing
- Frozen: blueberries

Joseph Doyle, MIT Sloan

## **Potential Mechanisms for Improved Health**

**1**. Lowers the cost of eating healthy meals

Relative price

Learn how to prepare healthy meals (diet education)

- 2. Education about diabetes and self care
- **3.** Income effect
- 4. Lowers stigma associated with food bank take-up  $\rightarrow$  Lowers food insecurity
- 5. Improves self-efficacy / control  $\rightarrow$  Improved adherence to healthy behaviors
- 6. Improves engagement with healthcare



## **Background: The intervention**

More intensive than most: more food; 1 year +

Food is curated by the dietitians

Clinic-based approach may facilitate education take-up

Annual variable costs are ~\$2000 per patient per year (food largely donated)

Small pilot study pre-post comparison:

1-2 point drop in HbA1c

80% drop in healthcare costs over 18 months

Influential: similar facilities opening around the country





Eligibility:

Age ≥ 18; HbA1c ≥ 8.0 Food insecure (2-question instrument) Residential ZIP ≤ 25 miles from a clinic

Recruitment

Phone calls and physician referrals Consent over the phone

Randomization

Stratified by: HbA1c > 9.5 and Site

Treatment: Start Now

Control: Start in 6 months + mailed a brochure that lists addresses of area food banks

#### **Data Sources**

- 1. Lab results (HbA1c, cholesterol, triglycerides, blood pressure, weight) at 0, 6 and 12 months into the program
- 2. Surveys at 0, 6, and 12 months into the program

Questions about diet, exercise, and smoking Questions about diabetes self-management behaviors, best practices, knowledge Questions about preventive healthcare Self-efficacy questionnaire (perseverance) Self-assessed physical and mental health

\$50 gift card for completion of #1 and #2



#### **Data Sources**

- **3.** Electronic Health Records
- 4. Health Plan paid claims (40% are plan participants)
- 5. Program participation data (including food visits, education)



## Intent to Treat $Y_i = \beta_0 + \beta_1 1 (\text{Treatment})_i + \beta_2 X_i + \varepsilon_i$


Primary outcome: HbA1c after 6 months into the study Secondary outcomes:


HbA1c after 12 months into the study (12 vs 6 months of the program) Other biometrics Utilization

Survey answers

Controls include lag of dependent variable, age, race, sex, and days between baseline (used for study enrollment) and follow-up test results

#### Figure 1: Screening, Randomization, and Analysis






Joseph Doyle, MIT Sloan


	Overall	Control	Treatment
Characteristic	(N=465)	(N=235)	(N=230)
Baseline outcome			
HbA1c	10.29	10.29	10.30
Demographics			
Age	54.6	54.4	54.8
Non-Hispanic Black (%)	8.82	7.66	10.0
Hispanic (%)	8.39	9.79	6.96
Male (%)	45.2	46.8	43.5
Location			
Rural (%)	28.2	28.5	27.8
Urban (%)	71.8	71.5	72.2
Prior-year Utilization			
Any inpatient admission (%)	23.0	20.4	25.7
Any ED visit (%)	41.1	40.0	42.2
Metformin prescription (%)	49.7	49.4	50.0
Any diabetes prescription	87.1	87.7	86.5
ERH DOVIE MIT SLOAN			

Timeframe:	6 months		12 months		Obs.
	Control	Treatment	Control	Treatment	
<b>Program tracking measures</b> Number of months with at					
least one visit	0.36	4.91	4.58	9.26	349
Mean number of visits	0.72	13.0	10.64	23.4	349

Median days in the program: 342



Joseph Doyle, MIT Sloan



Joseph Doyle, MIT Sloan

Timeframe:	6 months				
	Control	Treatment	-	ed Difference 95% Cl)	Obs.
Services provided at the clinic		neatherit	ſ		
Met a dietitian in past year	0.538	0.901	0.343	(0.253,0.432)	333
Taken a diabetes class in the past year	0.053	0.208	0.153	(0.080,0.225)	335
Received a diabetic foot exam in the past year	0.596	0.707	0.108	(0.008,0.208)	335
Engagement/preventive care index	0	0.402	0.364	(0.166,0.561)	335

#### 6-Month Survey Results

	Control mean	SD	Adjusted Difference for Full Controls (95% CI) Obs
Positive Diet Index			
Number of times ate fruit past wk	5.241	3.398	0.306 (-0.434,1.047) 333
Number of times ate dark green vegs past wk	4.012	2.901	2.182 (-0.827,5.192) 333
No. times drank sweetened beverages past wk	3.407	4.495	-0.528 (-1.393,0.337) 329
Never eats fast food/takeout/restaurant	0.363	0.482	0.058 (-0.048,0.163) 335
Diet improved from one year ago	0.772	0.421	0.172 (0.095,0.249) 335
Positive diet index	0.000	1.000	0.382 (0.188,0.576) 335


#### 6-Month Survey Index Results

	Control mean	SD		ted Difference Controls (95% CI)	Obs
Engagement/preventive care index	0.000	1.000	0.364	(0.166,0.561)	335
Positive diet index	0.000	1.000	0.382	(0.188,0.576)	335


#### 6-Month Survey Index Results

	Control mean	SD	5	ed Difference ontrols (95% CI)	Obs
Engagement/preventive care index	0.000	1.000	0.364	(0.166,0.561)	335
Positive diet index	0.000	1.000	0.382	(0.188,0.576)	335
Patient diabetes knowledge score	0.776	0.147	0.045	(0.012,0.078)	330
Exercise and smoking index	0.000	1.000	0.063	(-0.164,0.290)	335
Lowering barriers to healthy eating index	0.000	1.000	0.082	(-0.109,0.274)	335
Positive healthy attitudes index	0.000	1.000	0.137	(-0.062,0.335)	334
Positive self efficacy index	0.000	1.000	-0.058	(-0.277,0.160)	335
Positive health & wellbeing index	0.000	1.000	0.201	(-0.021,0.424)	335

Outcomes: Lab Results Control **Treatment** 







Joseph Doyle, MIT Sloan

#### **Effects on Biometric Outcomes at 6 months**

	Control		Adjusted			
	mean	SD	for Full Controls (95% CI)		Obs.	
HbA1c	8.82	1.98	-0.018	(-0.375 <i>,</i> 0.339)	349	

#### **Effects on Biometric Outcomes at 6 months**

	Control		Adjuste		
	mean	SD	for Full Co	for Full Controls (95% CI)	
HbA1c	8.82	1.98	-0.018	(-0.375,0.339)	349
LDL Cholesterol	85.5	36.8	6.80	(-1.21,14.81)	85.5
HDL Cholesterol	41.9	12.1	-0.649	(-2.98,1.68)	41.9
Total Cholesterol	161	48.2	4.31	(-6.10,14.73)	161
Triglycerides	202	158	11.5	(-19.24,42.17)	202
Fasting Glucose	198	100	-13.5	(-35.36,8.42)	198

#### **Effects on Biometric Outcomes at 6 months**

	Control	Adjusted Difference				
	mean	SD	for Full Cor	ntrols (95% CI)	Obs.	
HbA1c	8.82	1.98	-0.018	(-0.375,0.339)	349	
LDL Cholesterol	85.5	36.8	6.80	(-1.21,14.81)	307	
HDL Cholesterol	41.9	12.1	-0.649	(-2.98,1.68)	308	
Total Cholesterol	161	48.2	4.31	(-6.10,14.73)	308	
Triglycerides	202	158	11.5	(-19.24,42.17)	309	
Fasting Glucose	198	100	-13.5	(-35.36,8.42)	264	
Weight kg	108	30.1	1.62	(0.04,3.19)	400	
BMI	38.0	10.4	0.057	(-0.49,0.61)	340	
Systolic BP	129	19.8	-0.75	(-4.35,2.85)	378	
Diastolic BP	75	10.8	0.92	(-1.20,3.03)	378	

### **Effects on Biometric Outcomes at 12 Months**

	Control		Adjusted Difference		
	mean	SD	for Full C	Obs.	
HbA1c	8.60	2.04	0.114	(-0.285,0.513)	325

### **Effects on Biometric Outcomes at 12 Months**

	Control	Adjusted Difference			
	mean	SD	for Full C	ontrols (95% CI)	Obs.
HbA1c	8.60	2.04	0.114	(-0.285,0.513)	325
Triglycerides	225	270	0.615	(-37.08,38.31)	275
Fasting Glucose	172	68.2	10.6	(-9.44,30.63)	208
LDL Cholesterol	85.2	36.4	3.24	(-4.92,11.40)	271
HDL Cholesterol	43.7	17.1	-1.78	(-5.48,1.92)	278
Total Cholesterol	165	57.0	-0.85	(-12.26,10.57)	278
Weight (kg)	108	28.8	0.62	(-0.85,2.10)	368
Systolic BP	130	18.4	-2.53	(-6.15,1.09)	350
Diastolic BP	74.1	10.6	1.12	(-0.95 <i>,</i> 3.19)	350

# Outcome: Utilization

Joseph Doyle, MIT Sloan

### **Effects on 6-month Utilization Measures**

	Control Mean	SD	Adjusted (95	Obs.	
Number of inpatient or ED admissions	0.791	1.68	-0.051 (-	-0.287,0.185)	465
Number of outpatient visits	7.136	6.59	1.686 (	0.646,2.725)	465

### **Effects on 12-month Utilization Measures**

	Control Mean	SD	Adjusted Difference (95% CI)		Obs.	
Number of inpatient or ED admissions	1.498	3.35	-0.154	(-0.582,0.273)	465	
Number of outpatient visits	16.02	13.56	0.166	(-1.671,2.003)	465	

## **Effects on Prescription Drug Usage at 6 Months**

	Control Mean	SD	5	ed Difference ontrols (95% CI)	Obs.
Active Prescription: Insulin	0.515	0.501	0.026	(-0.040,0.093)	465
Active Prescription: Metformin	0.506	0.501	0.068	(0.004,0.133)	465
Active Prescription: Sulfonylureas	0.174	0.38	-0.009	(-0.051,0.033)	465
Active Prescription: GLP-1 & related	0.4	0.491	0.102	(0.026,0.178)	465
Active Prescription: Any Diabetes Medication	0.928	0.26	0.025	(-0.014,0.063)	465

### Effects on Prescription Drug Usage at 12 Months

	Control Mean	SD	,	ed Difference ontrols (95% CI)	Obs.
Active Prescription: Insulin	0.515	0.501	0.027	(-0.047,0.102)	465
Active Prescription: Metformin	0.468	0.5	0.086	(0.016,0.157)	465
Active Prescription: Sulfonylureas	0.17	0.377	-0.014	(-0.066,0.037)	465
Active Prescription: GLP-1 & related	0.409	0.493	0.037	(-0.046,0.119)	465
Active Prescription: Any Diabetes Medication	0.923	0.267	0.032	(-0.008,0.072)	465

## **Effects on 6-month Claims**

	Control Mean	SD	Adjusted Difference (95% CI) Obs	Obs.
Inpatient claims (\$)	\$1,408	\$4,007	-\$218 (-1473,1037) 201	L
ED claims (\$)	\$753	\$2,150	-\$113 (-572,347) 201	L
Inpatient or ED claims (\$)	\$2,162	\$5,285	-\$320 (-1803,1162) 201	L
Outpatient claims (\$)	\$2,023	\$3,493	\$1,439 (-245,3123) 201	L
Total claims (\$)	\$5,368	\$7,993	\$739 (-2004,3482) 201	L

### Effects on 12-month Claims

	Control Mean	SD	5	Adjusted Difference (95% CI)	
Inpatient claims (\$)	\$3,040	\$7,270	-\$1,131	(-3144,883)	183
ED claims (\$)	\$1,505	\$4,663	-\$572	(-1473,330)	183
Inpatient or ED claims (\$)	\$4,545	\$9,951	-\$1,678	(-4125,769)	183
Outpatient claims (\$)	\$4,118	\$5,206	\$1,380	(-743,3504)	183
Total claims (\$)	\$11,082	\$14,797	-\$774	(-4896,3349)	183

We lack statistical power to differentiate subgroups but can look for suggestive differences.

Qualitatively similar across a number of subgroups:

- Strata (baseline A1c, and Site)
- Men/Women
- Single-households vs. Multi-person households
- High/low utilization prior to joining the study
- Payer

Pre-COVID & Post-COVID



# We find a null effect on HbA1c

# We do find substantial effects on diet and healthcare engagement

Preventive care

» Program healthcare: Dietitian appointments, foot exams

» Increase in outpatient visits and claims

» Increase in metformin and modern glucose-lowering-drug prescriptions

Diabetes Knowledge

# We find null effects on:

Diabetes self-efficacy; other healthy behaviors (exercise; smoking);

# We find statistically-insignificant improvement in self-assessed health & reduction in inpatient/ed utilization



Study demonstrates the value of a control group Programs targeted to elevated biomarkers  $\rightarrow$  mean reversion

Context: patients connected to a health system

Food as Medicine: many parameters Mode (home delivery vs. produce prescription) Duration; Amount of food; Coupled with Education



# Thank you



#### MEDICAL REPORT JANUARY 24, 2011 ISSUE

# THE HOT SPOTTERS


Can we lower medical costs by giving the neediest patients better care?



By Atul Gawande


January 17, 2011

# Program participants visited the hospital about 40% less in the six months post-intervention



Joseph Doyle, MIT Sloan

# Clinical trial findings: Control group mirrors treatment group →No effect on re-hospitalization



Joseph Doyle, MIT Sloan

1.2